"rationale","instanceType","versionIdentifier","uuid:ID","id"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion","2","c1476bba-5595-40e7-91c6-f35097ce2c98","StudyVersion_1"
